Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Inclusion Criteria: * Have a newly diagnosed, biopsy-proven adenocarcinoma of the pancreas. * Tumor must be deemed resectable by the study team * Patient's acceptance to have a tumor biopsy. * Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1. * Patients must have adequate organ and marrow function defined by study-specified laboratory tests and procedures. * Women of childbearing potential (WOCBP) must have a negative serum pregnancy test. * For both Women and Men, must use acceptable form of birth control while on study. Exclusion Criteria: * Received any anti-pancreatic cancer therapy (symptomatic therapies are allowed), or any prior anti-cancer immunotherapy. * Diagnosed with another cancer whose natural history or treatment could interfere with safety or efficacy assessments on this study. * Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements. * Active autoimmune disease. * Systemic steroid therapy (\> 10mg daily prednisone equivalent) or immunosuppressive therapy within 14 days of first dose of study drug administration. * Active infection requiring systemic therapy. * Known history of human immunodeficiency virus (HIV). * Active or chronic hepatitis B or hepatitis C. * Known active tuberculosis. * History of interstitial lung disease, non-infectious pneumonitis or uncontrolled lung diseases including pulmonary fibrosis, acute lung diseases, chronic obstructive pulmonary disease (COPD), asthma requiring medication, etc. * Prior allogeneic stem cell transplantation or organ transplantation. * Any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of study drug. * Received a live vaccine ≤ 28 days before first dose of study drug. * History of severe hypersensitivity reaction to any monoclonal antibody * Concurrent participation in another therapeutic clinical study * Pregnant or breastfeeding